Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

BioTime to Webcast Presentation at the Ladenburg Thalmann 2016 Healthcare Conference

BioTime,Inc.
Posted on: 23 Sep 16

BioTime, Inc. (NYSE MKT:BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that itwill be presenting at the Ladenburg Thalmann 2016 Healthcare Conference in New York City on Tuesday, September 27, 2016, at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time.

The Ladenburg Thalmann Healthcare Conference is a well-respected event for investors who are specifically focused on healthcare and life sciences companies such as BioTime. This venue allows BioTime’s management to provide a corporate overview and update on its product development.

Attendance is by invitation only. However, the presentation will be webcast live and will also be available for replay at the “Events & Presentations” page of the “Investors & Media” section on BioTime’s website at http://www.biotimeinc.com/.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world’s premier collection of pluripotent cell assets. The foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

In addition to the development of therapeutics, BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160923005182/en/

Business Wire
www.businesswire.com

Last updated on: 23/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.